Myomo (NYSEAMERICAN:MYO) Director Acquires 70,000 Shares

Myomo, Inc. (NYSEAMERICAN:MYO) Director Heather Getz acquired 70,000 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $51,100.00. Following the transaction, the director directly owned 111,754 shares of the company’s stock, valued at approximately $81,580.42. The trade was a 167.65% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Myomo Trading Down 3.7%

Shares of Myomo stock traded down $0.03 during trading on Thursday, hitting $0.69. The stock had a trading volume of 469,515 shares, compared to its average volume of 513,649. Myomo, Inc. has a 12 month low of $0.64 and a 12 month high of $5.62. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.30 and a quick ratio of 2.10. The firm’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $0.92. The stock has a market cap of $26.45 million, a PE ratio of -1.86 and a beta of 1.17.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Ascendiant Capital Markets reduced their price target on Myomo from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, November 21st. Craig Hallum reaffirmed a “buy” rating on shares of Myomo in a research report on Tuesday. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Myomo has an average rating of “Buy” and an average target price of $7.67.

Key Myomo News

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: Director Heather C. Getz purchased 70,000 shares at an average $0.73, raising her direct ownership to 111,754 shares — a sizable insider buy that can be interpreted as management confidence in the company’s outlook. SEC Filing
• Neutral Sentiment: Q4 2025 earnings call noted record revenue but rising expenses and margin pressure — revenue strength is encouraging for growth, but higher costs weigh on near‑term profitability and cash needs. Earnings Call Highlights
• Neutral Sentiment: HC Wainwright published a long‑range FY2030 estimate (EPS $0.35), which suggests potential long‑term upside if execution and reimbursement trends improve, but this is far‑term and speculative. MarketBeat MYO
• Negative Sentiment: HC Wainwright cut near‑term and multi‑year EPS forecasts across Q1–Q3 2026 and FY2026–FY2029 (e.g., FY2026 to ($0.34) from ($0.31); FY2027 to ($0.22) from ($0.15); FY2028 to ($0.05) from $0.07; FY2029 to $0.16 from $0.30). These downward revisions tighten the outlook and likely pressured the stock. Analyst Note
• Negative Sentiment: Myomo flagged new high‑risk language in forward‑looking statements — highlighting concerns around reimbursement, financing and growth plans — which raises execution and funding risk for investors. Risk Disclosure

Institutional Trading of Myomo

A number of large investors have recently modified their holdings of the company. Rosalind Advisors Inc. grew its stake in Myomo by 1.3% in the fourth quarter. Rosalind Advisors Inc. now owns 3,839,772 shares of the company’s stock worth $3,494,000 after purchasing an additional 48,984 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of Myomo in the 4th quarter worth $641,000. Geode Capital Management LLC lifted its holdings in shares of Myomo by 160.8% in the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock worth $1,446,000 after buying an additional 412,631 shares during the period. Stonepine Capital Management LLC grew its position in shares of Myomo by 65.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 457,419 shares of the company’s stock worth $988,000 after buying an additional 180,712 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Myomo by 47.8% during the fourth quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock valued at $395,000 after buying an additional 140,427 shares during the period. Hedge funds and other institutional investors own 44.99% of the company’s stock.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.